<DOC>
	<DOCNO>NCT00709904</DOCNO>
	<brief_summary>The primary objective evaluate efficacy daily ( QD ) subcutaneous ( SC ) injection Semuloparin sodium ( AVE5026 ) versus placebo 3 additional week follow initial 7 10-day venous thromboprophylaxis open-label AVE5026 patient undergone hip fracture surgery . The secondary objective evaluate safety extend AVE5026 administration .</brief_summary>
	<brief_title>Evaluation AVE5026 Compared Placebo Extended Prophylaxis Venous Thromboembolism Patients Having Undergone Hip Fracture Surgery</brief_title>
	<detailed_description>The total duration observation per participant 56-63 day surgery broken follow : - 7 10-day initial treatment period open-label Semuloparin sodium ; - Randomization ; - 19 23-day double-blind treatment period Semuloparin sodium placebo ; - 30-day follow-up period . Mandatory bilateral venography lower limb perform 19 24 day randomization .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>In runin phase : Standard surgery fracture upper third femur , include femoral head neck In doubleblind phase follow runin phase : Completion runin phase without permanent treatment discontinuation Any major orthopedic surgery within 3 month prior enrolment ; Deep vein thrombosis pulmonary embolism within last 12 month , know postphlebitic syndrome ; High risk bleeding ; Known hypersensitivity heparin ; Any contraindication performance venography ; End stage renal disease patient dialysis The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>venous thromboprophylaxis</keyword>
	<keyword>primary prevention</keyword>
	<keyword>orthopedic surgery</keyword>
</DOC>